CLOSED: Feasibility trial (Phase I) regarding the use of nano-cancer therapy in LOCAL RESIDUAL TUMORS OF DIFFERING ENTITIES

The study is to verify the feasibility of nano-cancer therapy with locally limited tumors without remote metastasis. This includes residual tumors, e.g. of sarcomas, rectal, pancreatic, bronchial, cervical, esophageal or mammary carcinoma in which all conventional therapy options were exhausted.

Study title

Magnetic fluid hyperthermia (MFH or "nano-cancer therapy") as an effect-boosting measure in interstitial radiotherapy (afterloading procedure or seed implantation) and/or radio(chemo)therapy of solitary or oligotopic previously treated recurrent cancers

Principal investigators

Prof. Dr. Peter Wust, Clinic for Radiation Medicine, Charité University Medicine Berlin
Prof. Dr. Jens Ricke, Clinic for Radiation Medicine, Charité University Medicine Berlin

Study duration

February 2004 - August 2007

Inclusion criteria

• Previously irradiated inoperable tumor, max. 4.5 cm diameter, no other tumor manifestations
• The option of adjuvant radiation and/or chemotherapy is available
• Karnofsky Index ≥ 70%
• No metal structures (prostheses, implants, metal splinters, etc.) near the treatment region (approximately 40cm). Surgical clips and similar objects are permitted
• Male > 18 years or post-menopausal female or after hysterectomy
• No cardiac pacemaker or other electronic implant
  
• Patient declaration of consent